[go: up one dir, main page]

MA48480A - Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin - Google Patents

Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin

Info

Publication number
MA48480A
MA48480A MA048480A MA48480A MA48480A MA 48480 A MA48480 A MA 48480A MA 048480 A MA048480 A MA 048480A MA 48480 A MA48480 A MA 48480A MA 48480 A MA48480 A MA 48480A
Authority
MA
Morocco
Prior art keywords
blood plasma
cognitive
treatment
dosage schedule
products
Prior art date
Application number
MA048480A
Other languages
English (en)
Inventor
Steven P Braithwaite
Eva Czirr
Ian Gallager
Nina Huber
S Sakura Minami
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of MA48480A publication Critical patent/MA48480A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/017—Hydrolysed proteins; Derivatives thereof from animals from blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
MA048480A 2017-04-26 2018-04-24 Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin MA48480A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762490519P 2017-04-26 2017-04-26
US201762584571P 2017-11-10 2017-11-10
US201862623468P 2018-01-29 2018-01-29
US201862641194P 2018-03-09 2018-03-09

Publications (1)

Publication Number Publication Date
MA48480A true MA48480A (fr) 2020-03-04

Family

ID=63915938

Family Applications (1)

Application Number Title Priority Date Filing Date
MA048480A MA48480A (fr) 2017-04-26 2018-04-24 Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin

Country Status (20)

Country Link
US (3) US10357513B2 (fr)
EP (2) EP4299129A3 (fr)
JP (3) JP7625364B2 (fr)
KR (1) KR20190135059A (fr)
CN (2) CN110709098B (fr)
AU (2) AU2018257921B2 (fr)
BR (1) BR112019022402A2 (fr)
CA (1) CA3061194A1 (fr)
CL (1) CL2019003076A1 (fr)
CO (1) CO2019012385A2 (fr)
DK (1) DK3615057T3 (fr)
ES (1) ES2971462T3 (fr)
IL (2) IL305904A (fr)
MA (1) MA48480A (fr)
MX (1) MX2019012795A (fr)
SG (1) SG11201909927RA (fr)
TW (2) TW202332455A (fr)
UA (1) UA127828C2 (fr)
WO (1) WO2018200560A1 (fr)
ZA (1) ZA202301009B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015123603A1 (fr) * 2014-02-14 2015-08-20 Beth Israel Deaconess Medical Center, Inc. Myographie d'impédance électrique
MY202968A (en) * 2016-08-18 2024-05-31 Alkahest Inc Blood plasma fractions as a treatment for aging-associated cognitive disorders
MA48480A (fr) 2017-04-26 2020-03-04 Alkahest Inc Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin
EP3793602A4 (fr) 2018-05-15 2022-04-20 Alkahest, Inc. Traitement d'une maladie associée au vieillissement avec des modulateurs de la leucotriène a4 hydrolase
BR112021000653A2 (pt) * 2018-07-20 2021-04-13 Alkahest, Inc. Regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo
CN119345230A (zh) * 2018-10-26 2025-01-24 万能溶剂有限公司 血浆和血浆组分用于改善疼痛的用途
CN113194840A (zh) * 2018-12-17 2021-07-30 株式会社夏目综合研究所 脑疾病的诊断装置
GB201904810D0 (en) 2019-04-05 2019-05-22 Cynapsedx Ltd The treatment of protein aggregation diseases
JP7432711B2 (ja) * 2019-09-17 2024-02-16 エフ． ホフマン－ラ ロシュ アーゲー 動作障害患者に対する個別化医療の改善
AU2020378245A1 (en) 2019-11-04 2022-04-07 Alkahest, Inc. Blood plasma fractions for use in muscle regeneration
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
AU2020388572A1 (en) 2019-11-20 2022-05-26 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
CA3200309A1 (fr) * 2020-10-30 2022-05-05 Shenzhen Protgen Ltd. Utilisation d'albumine serique humaine dans le traitement de maladies
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases
EP4216225A1 (fr) * 2022-01-20 2023-07-26 Koninklijke Philips N.V. Appareil de détermination de la déficience cognitive
EP4551236A1 (fr) * 2022-07-06 2025-05-14 Yuvan Research, Inc. Compositions anti-vieillissement enrichies en arn et leurs utilisations

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3869431A (en) 1973-03-12 1975-03-04 Firestone Tire & Rubber Co Polyamides and their production
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
US4708713A (en) 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
DE3612137A1 (de) 1986-04-10 1987-10-15 Biotest Pharma Gmbh Steriles plasmaaustauschmittel
US5110907A (en) 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5219995A (en) 1992-07-14 1993-06-15 Alpha Therapeutic Corporation Plasma fraction purification
US6544761B2 (en) 1994-12-13 2003-04-08 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
US5916202A (en) 1996-08-30 1999-06-29 Haswell; John N. Umbilical cord blood collection
US6416487B1 (en) 1997-07-30 2002-07-09 Renal Tech International Llc Method of removing beta-2 microglobulin from blood
UA35656C2 (uk) 1999-12-27 2001-04-16 Олександр Миколайович Макаренко Спосіб лікування безперервно прогредієнтних ослабоумлюючих психічних захворювань
US6946546B2 (en) 2000-03-06 2005-09-20 Cambridge Antibody Technology Limited Human antibodies against eotaxin
US6632174B1 (en) 2000-07-06 2003-10-14 Cognifit Ltd (Naiot) Method and apparatus for testing and training cognitive ability
US20020151064A1 (en) 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
US20040127445A1 (en) 2002-08-28 2004-07-01 Chondrogene Limited Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
US20040120937A1 (en) 2002-12-19 2004-06-24 Therapy Patent Corporation Blood therapy process
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
GB0305133D0 (en) 2003-03-06 2003-04-09 Sinvent As Product
DK1608374T5 (da) 2003-03-24 2010-01-25 Axikin Pharmaceuticals Inc 2-Phenoxy- og 2-phenylsulfanylbenzensulfonamidderivater med CCR3-antagonistisk aktivitet til behandling af astma og andre inflammatoriske eller immunologiske sygdomme
EP1622577A4 (fr) 2003-04-17 2007-09-26 Univ Leland Stanford Junior Prevention des troubles de neurogenese deficitaire a l'aide d'agents anti-inflammatoires
EP1692520A2 (fr) 2003-11-19 2006-08-23 Satoris, Inc. Methodes et compositions pour le diagnostic, la stratification et la surveillance de la maladie d'alzheimer
US20060094064A1 (en) 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
US20130121979A1 (en) * 2003-12-29 2013-05-16 Allan Mishra Method of treating cancer using platelet compositions
WO2005106492A2 (fr) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostic et traitement therapeutique des maladies associees au recepteur 3 de la chimiokine c-c (ccr3)
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
WO2007059135A2 (fr) 2005-11-10 2007-05-24 Satoris, Inc. Procedes destines a traiter la maladie d’alzheimer
US10344095B2 (en) 2006-02-16 2019-07-09 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
ES2257225B1 (es) 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
JP2009149524A (ja) 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
WO2007123976A2 (fr) 2006-04-18 2007-11-01 The Board Of Trustees Of The Leland Stanford Junior University Établissement de profils d'anticorps pour la détermination de la sensibilité des patients à un traitement
WO2007146229A2 (fr) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Marqueurs associés à des événements artério-vasculaires et procédés d'utilisation de ces marqueurs
US7592009B2 (en) 2006-10-10 2009-09-22 Ecole Polytechnique Federale De Lausanne (Epfl) Polypeptide ligands for targeting cartilage and methods of use thereof
BRPI0815551A2 (pt) 2007-08-15 2015-02-18 Univ South Florida Tratamento através de hucbc de doença beta-amiloide
WO2009051660A2 (fr) 2007-10-12 2009-04-23 The Board Of Trustees Of The Leland Stanford Junior University Composés permettant l'activation de la signalisation tgf-bêta
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20100310609A1 (en) 2007-10-25 2010-12-09 Revalesio Corporation Compositions and methods for treatment of neurodegenerative diseases
ES2332846B1 (es) 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
KR101177199B1 (ko) 2007-12-06 2012-08-24 아사히 가세이 메디컬 가부시키가이샤 혈액 처리용 다공질 중공사막
WO2009129226A1 (fr) 2008-04-15 2009-10-22 Talecris Biotherapeutics, Inc. Ultrafiltration/diafiltration a deux phases
US20090297485A1 (en) * 2008-05-28 2009-12-03 Allan Mishra Compositions and methods for treating psychiatric and neurodegenerative disorders
US20100124756A1 (en) 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
US20110117100A1 (en) 2008-11-03 2011-05-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for diagnosis, stratification and treatment of amyloidogenic diseases
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US20130040844A1 (en) 2010-01-28 2013-02-14 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers of aging for detection and treatment of disorders
WO2017120461A1 (fr) 2016-01-08 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Modulation du ccr3 pour le traitement de déficiences associées au vieillissement, et compositions utilisées pour cette modulation
WO2016187217A2 (fr) 2015-05-18 2016-11-24 The Board Of Trustees Of The Leland Stanford Junior University Méthodes et compositions permettant de traiter des troubles associés au vieillissement
US20110202284A1 (en) 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
RU2428997C1 (ru) 2010-03-01 2011-09-20 Федеральное государственное образовательное учреждение высшего профессионального образования Волгоградская государственная сельскохозяйственная академия Способ получения лечебных препаратов из пуповины плода
AR080698A1 (es) 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
US8206715B2 (en) 2010-05-04 2012-06-26 Five Prime Therapeutics, Inc. Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
RU2470677C1 (ru) 2011-10-19 2012-12-27 Надежда Михайловна Цулая Способ стимуляции репаративных и трофических процессов в коже
CN104884611A (zh) 2012-02-13 2015-09-02 孔五一 Nprcp、pfdnc和它们的应用
JP2015515462A (ja) 2012-03-20 2015-05-28 イェシバ・ユニバーシティＹｅｓｈｉｖａ Ｕｎｉｖｅｒｓｉｔｙ 輸血の有効性を高める方法
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US20150217046A1 (en) * 2012-06-05 2015-08-06 Synagile Corporation Dosing regimens for subcutaneously infusible acidic compositions
RU2635560C2 (ru) 2012-10-29 2017-11-14 Чайна Петролеум Энд Кемикал Корпорейшн Способ адсорбционной десульфуризации углеводородов и реакторное устройство для его осуществления
HUE044737T2 (hu) * 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
US20150061767A1 (en) 2013-08-28 2015-03-05 Texas Instruments Incorporated Telescopic Amplifier with Improved Common Mode Settling
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
AU2014364182B2 (en) * 2013-12-09 2019-03-07 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
ES2524516B1 (es) 2014-05-29 2015-03-31 Grifols Worldwide Operations Limited Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido
CA2989138C (fr) 2015-06-15 2022-11-22 The Board Of Trustees Of The Leland Stanford Junior University Procedes et compositions pour le traitement d'un trouble cognitif ou d'un declin cognitif comprenant un inhibiteur tissulaire de la metalloproteinase-2 (timp-2)
US11628190B2 (en) * 2015-08-28 2023-04-18 University Of South Florida Plasma derived from human umbilical cord blood for the treatment of neurodegenerative disorders
US10525107B2 (en) 2016-08-18 2020-01-07 Alkahest, Inc. Blood plasma fractions as a treatment for aging-associated cognitive disorders
MY202968A (en) * 2016-08-18 2024-05-31 Alkahest Inc Blood plasma fractions as a treatment for aging-associated cognitive disorders
MA48480A (fr) 2017-04-26 2020-03-04 Alkahest Inc Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin

Also Published As

Publication number Publication date
US20210060063A1 (en) 2021-03-04
ES2971462T3 (es) 2024-06-05
TW202332455A (zh) 2023-08-16
TW201841646A (zh) 2018-12-01
CL2019003076A1 (es) 2020-01-31
IL270125B1 (en) 2023-10-01
JP2020517693A (ja) 2020-06-18
TWI782009B (zh) 2022-11-01
US10357513B2 (en) 2019-07-23
NZ758615A (en) 2023-09-29
WO2018200560A1 (fr) 2018-11-01
IL305904A (en) 2023-11-01
AU2018257921A1 (en) 2019-11-14
EP4299129A3 (fr) 2024-03-20
IL270125A (fr) 2019-12-31
US10874692B2 (en) 2020-12-29
KR20190135059A (ko) 2019-12-05
AU2018257921B2 (en) 2024-06-06
CA3061194A1 (fr) 2018-11-01
EP3615057A4 (fr) 2020-09-30
US20190282617A1 (en) 2019-09-19
CO2019012385A2 (es) 2020-01-17
EP3615057B1 (fr) 2023-11-29
EP4299129A2 (fr) 2024-01-03
US11413308B2 (en) 2022-08-16
SG11201909927RA (en) 2019-11-28
JP2023036856A (ja) 2023-03-14
CN110709098B (zh) 2024-01-30
JP2025000786A (ja) 2025-01-07
BR112019022402A2 (pt) 2020-05-19
ZA202301009B (en) 2023-10-25
CN117899111A (zh) 2024-04-19
EP3615057A1 (fr) 2020-03-04
JP7625364B2 (ja) 2025-02-03
MX2019012795A (es) 2020-02-13
CN110709098A (zh) 2020-01-17
UA127828C2 (uk) 2024-01-17
AU2024216537A1 (en) 2024-09-19
US20180311280A1 (en) 2018-11-01
IL270125B2 (en) 2024-02-01
DK3615057T3 (da) 2024-01-02

Similar Documents

Publication Publication Date Title
MA48480A (fr) Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin
EP3370748A4 (fr) Microbiote thérapeutique pour le traitement et/ou la prévention de l'allergie alimentaire
MA53182A (fr) Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits à base de plasma sanguin
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
EP3377220A4 (fr) Catalyseur pour le traitement de gaz d'échappement
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
EP3533466A4 (fr) Composition pharmaceutique pour le traitement et/ou la prévention du cancer
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
IL258476A (en) Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
EP3291693A4 (fr) Régime alimentaire imitant et favorisant le jeûne pour le traitement de l'hypertension et des troubles lipidiques
FR3032353B1 (fr) Composition pharmaceutique et dispositif pour le traitement de la douleur
EP3716972A4 (fr) Immunomodulateurs à base de pyranopyrazole et de pyrazolopyridine pour le traitement de maladies auto-immunes
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
MA42657A (fr) Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
EP3259600C0 (fr) Dosage diagnostique et traitement de la pré-éclampsie
EP3370725A4 (fr) Dosage pédiatrique pour le traitement du cancer avec un inhibiteur d'ezh2
PT3334693T (pt) Processo e sistema para o tratamento contínuo de águas residuais.
EP3496708C0 (fr) Métabolites pour le traitement et la prévention de maladie auto-immune
FR3020951B1 (fr) Association d'un tetrapeptide et d'un glyceryl ester pour le traitement de l'alopecie androgenique.
FR3022139B1 (fr) Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee
FR3044227B1 (fr) Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
EP3302529A4 (fr) Compositions et procédés pour le traitement de l'atrésie des voies biliaires néonatale
EP3395350A4 (fr) Médicament pour le traitement des infarctus cérébraux
EP3154538C0 (fr) Acide glycolique et/ou acide d-lactique pour le traitement de maladies neuro-dégératives